Skip to main content
SpringerLink
Log in

Pankreaskarzinom beim alten und geriatrischen Patienten

  • Chapter
  • First Online:
Geriatrische Onkologie

Part of the book series: Springer Reference Medizin ((SRM))

  • 1612 Accesses

Zusammenfassung

Das duktale Adenokarzinom des Pankreas ist eine Erkrankung des älteren Menschen, nahezu 2/3 aller neudiagnostizierten Fälle ist über 65 Jahre alt. Gleichzeitig werden mit zunehmendem Alter immer weniger Patienten in randomisierte Studie eingebracht, so dass insbesondere für das Pankreaskarzinom nur sehr wenige Daten zu Therapie und Therapie assoziierten Toxizitäten des älteren Menschen vorliegen. Aufgrund der zum Teil schweren Symptomatik (Kachexie, Schmerzexazerbationen, Ileus etc.) und der infausten Prognose sind jedoch im klinischen Alltag rationale Therapiealgorithmen essentiell. Das Kapitel soll in diesem Zusammenhang einen kurzen Überblick über die vorliegende Literatur zur Therapie hoch betagter Pankreaskarzinompatienten geben.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 159.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Bellera CA, Rainfray M et al (2012) Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol 23(8):2166–2172

    Article  CAS  PubMed  Google Scholar 

  • Berger AK, Abel U et al (2014) Chemotherapy for advanced pancreatic adenocarcinoma in elderly patients (>/=70 years of age): a retrospective cohort study at the national center for tumor diseases Heidelberg. Pancreatology 14(3):211–215

    Article  CAS  PubMed  Google Scholar 

  • Boeck S, Hoehler T et al (2008) Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Ann Oncol 19(2):340–347

    Article  CAS  PubMed  Google Scholar 

  • Burris HA 3rd, Moore MJ et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403–2413

    Article  CAS  PubMed  Google Scholar 

  • Callery MP, Chang KJ et al (2009) Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 16(7):1727–1733

    Article  PubMed  Google Scholar 

  • Casadei R, Zanini N et al (2006) Prognostic factors in periampullary and pancreatic tumor resection in elderly patients. World J Surg 30(11):1992–2001, Discussion 2002–1993

    Article  CAS  PubMed  Google Scholar 

  • Chauffert B, Mornex F et al (2008) Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 19(9):1592–1599

    Article  CAS  PubMed  Google Scholar 

  • Cohen HJ, Smith D et al (2016) Frailty as determined by a comprehensive geriatric assessment-derived deficit-accumulation index in older patients with cancer who receive chemotherapy. Cancer 122:3865–3872

    Article  PubMed  PubMed Central  Google Scholar 

  • Conroy T, Desseigne F et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817–1825

    Article  CAS  PubMed  Google Scholar 

  • Finlayson E, Fan Z et al (2007) Outcomes in octogenarians undergoing high-risk cancer operation: a national study. J Am Coll Surg 205(6):729–734

    Article  PubMed  Google Scholar 

  • Fong Y, Blumgart LH et al (1995) Pancreatic or liver resection for malignancy is safe and effective for the elderly. Ann Surg 222(4):426–434, Discussion 434–427

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Frakes JM, Strom T et al (2015) Resected pancreatic cancer outcomes in the elderly. J Geriatr Oncol 6(2):127–132

    Article  PubMed  Google Scholar 

  • Giordano G, De Vita F et al (2015) Analysis of activity, efficacy and safety of first line Nab Paclitaxel (Nab-P) and Gemcitabine (G) in advanced pancreatic cancer (APDAC) frail and elderly patients (pts). Eur J Cancer 51(3):445

    Article  Google Scholar 

  • Goldstein und El-Maraghi (2015) Nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst 107(2). Epub 02-02-2015. ISSN:1460-2105 (Electronic), 0027-8874 (Linking). https://doi.org/10.1093/jnci/dju413

  • Gunturu KS, Yao X et al (2013) FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol 30(1):361

    Article  PubMed  Google Scholar 

  • Hammel P, Huguet F et al (2016) Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA 315(17):1844–1853

    Article  CAS  PubMed  Google Scholar 

  • Heek NT van, Kuhlmann KF et al (2005) Hospital volume and mortality after pancreatic resection: a systematic review and an evaluation of intervention in the Netherlands. Ann Surg 242(6):781–788, Discussion 788–790

    Google Scholar 

  • Hentic O, Dreyer C et al (2011) Gemcitabine in elderly patients with advanced pancreatic cancer. World J Gastroenterol 17(30):3497–3502

    Article  PubMed  PubMed Central  Google Scholar 

  • Higuera O, Ghanem I et al (2016) Management of pancreatic cancer in the elderly. World J Gastroenterol 22(2):764–775

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ho V, Heslin MJ (2003) Effect of hospital volume and experience on in-hospital mortality for pancreaticoduodenectomy. Ann Surg 237(4):509–514

    PubMed  PubMed Central  Google Scholar 

  • Huguet F, Andre T et al (2007) Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25(3):326–331

    Article  CAS  PubMed  Google Scholar 

  • Ito Y, Kenmochi T et al (2011) The impact of surgical outcome after pancreaticoduodenectomy in elderly patients. World J Surg Oncol 9:102

    Article  PubMed  PubMed Central  Google Scholar 

  • James (2014) Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC). J Clin Oncol 32(Suppl 3):e15226

    Google Scholar 

  • Katopodis O, Polyzos A et al (2011) Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. Cancer Chemother Pharmacol 67(2):361–368

    Article  CAS  PubMed  Google Scholar 

  • Kotwall CA, Maxwell JG et al (2002) National estimates of mortality rates for radical pancreaticoduodenectomy in 25,000 patients. Ann Surg Oncol 9(9):847–854

    Article  PubMed  Google Scholar 

  • Mangano DT, Goldman L (1995) Preoperative assessment of patients with known or suspected coronary disease. N Engl J Med 333(26):1750–1756

    Article  CAS  PubMed  Google Scholar 

  • Marechal R, Demols A et al (2008) Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer. Pancreas 36(3):e16–e21

    Article  CAS  PubMed  Google Scholar 

  • Moore MJ (2013) Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC). J Clin Oncol 31(suppl, abstr 4059)

    Google Scholar 

  • Moore MJ, Goldstein D et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 25(15):1960–1966

    Article  CAS  PubMed  Google Scholar 

  • Nagrial AM, Chang DK et al (2014) Adjuvant chemotherapy in elderly patients with pancreatic cancer. Br J Cancer 110(2):313–319

    Article  CAS  PubMed  Google Scholar 

  • Nakai Y, Isayama H et al (2011) Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy. Crit Rev Oncol Hematol 78(3):252–259

    Article  PubMed  Google Scholar 

  • Neoptolemos JP, Stocken DD et al (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304(10):1073–1081

    Article  CAS  PubMed  Google Scholar 

  • Neoptolemos JP, Moore MJ et al (2012) Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 308(2):147–156

    Article  CAS  PubMed  Google Scholar 

  • Niess H, Kleespies A et al (2013) Pancreatic cancer in the elderly: guidelines and individualized therapy. Chirurg 84(4):291–295

    Article  CAS  PubMed  Google Scholar 

  • Oettle H, Neuhaus P et al (2013) Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 310(14):1473–1481

    Article  CAS  PubMed  Google Scholar 

  • Peddi PF, Lubner S et al (2012) Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP 13(5):497–501

    PubMed  Google Scholar 

  • Peixoto RD, Ho M et al (2015) Eligibility of metastatic pancreatic cancer patients for first-line palliative intent nab-Paclitaxel plus gemcitabine versus FOLFIRINOX. Am J Clin Oncol [Epub]

    Google Scholar 

  • Riall TS (2009) What is the effect of age on pancreatic resection? Adv Surg 43:233–249

    Article  PubMed  PubMed Central  Google Scholar 

  • Riall TS, Sheffield KM et al (2011) Resection benefits older adults with locoregional pancreatic cancer despite greater short-term morbidity and mortality. J Am Geriatr Soc 59(4):647–654

    Article  PubMed  PubMed Central  Google Scholar 

  • Seufferlein T, Adler G (2009) The S3 guideline exocrine pancreatic cancer. Med Klin (Munich) 104(11):869–874

    Article  Google Scholar 

  • Seufferlein T, Porzner M et al (2013) S3-guideline exocrine pancreatic cancer. Z Gastroenterol 51(12):1395–1440

    Article  CAS  PubMed  Google Scholar 

  • Shaib WL, Ip A et al (2016) Contemporary management of borderline resectable and locally advanced unresectable pancreatic cancer. Oncologist 21(2):178–187

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Siegel R, Ma J et al (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29

    Article  PubMed  Google Scholar 

  • Talarico L, Chen G et al (2004) Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US food and drug administration. J Clin Oncol 22(22):4626–4631

    Article  PubMed  Google Scholar 

  • Vickers MM, Powell ED et al (2012) Comorbidity, age and overall survival in patients with advanced pancreatic cancer – results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo. Eur J Cancer 48(10):1434–1442

    Article  CAS  PubMed  Google Scholar 

  • Wang-Gillam A, Li CP et al (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387(10018):545–557

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. II. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim und Abt. Gastroenterologie und Onkologie, Heilig-Geist Hospital Bensheim, Theodor-Kutzer-Ufer 1-3, 68167, Bensheim, Deutschland

    Nicolai Härtel

  2. Chirurgische Klinik, Universitätsmedizin Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Deutschland

    Felix Rückert

Authors
  1. Nicolai Härtel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Felix Rückert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicolai Härtel .

Editor information

Editors and Affiliations

  1. II. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany

    Matthias Ebert

  2. II. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany

    Nicolai Härtel

  3. Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany

    Ulrich Wedding

Section Editor information

  1. Interdisziplinäres Tumorzentrum, Universitätsmedizin Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Deutschland

    Nicolai Härtel

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Härtel, N., Rückert, F. (2018). Pankreaskarzinom beim alten und geriatrischen Patienten. In: Ebert, M., Härtel, N., Wedding, U. (eds) Geriatrische Onkologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-48727-3_26

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-48727-3_26

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-48726-6

  • Online ISBN: 978-3-662-48727-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation